Quick Comparison
| HGH Fragment 176-191 | Survodutide | |
|---|---|---|
| Half-Life | 0.5-1 hours | 144 hours (6 days) |
| Typical Dosage | Research: 250-500 mcg subcutaneous once or twice daily, on an empty stomach. Often cycled 8-12 weeks on, 4 weeks off. The short half-life typically requires twice-daily dosing for sustained effect. | Clinical trials: up to 6 mg subcutaneous once weekly. Dose escalation required over initial weeks starting at lower doses. Optimal dosing still being established in Phase 3. |
| Administration | Subcutaneous injection | Subcutaneous injection (weekly) |
| Research Papers | 1 papers | 30 papers |
| Categories |
Mechanism of Action
HGH Fragment 176-191
HGH Fragment 176-191 is the unmodified C-terminal segment of human growth hormone, representing exactly the last 16 amino acids of the 191-amino-acid GH molecule. Research identified this region as containing the molecular determinants responsible for GH's lipolytic activity, independent of the N-terminal domain that binds the growth hormone receptor and drives IGF-1 production and tissue growth.
The fragment activates lipolysis in white adipose tissue through interaction with beta-adrenergic signaling pathways. This triggers the cAMP/protein kinase A cascade that phosphorylates and activates hormone-sensitive lipase and perilipin proteins on the surface of lipid droplets within fat cells. The result is the breakdown of stored triglycerides into free fatty acids and glycerol, which are released into circulation for oxidation by energy-demanding tissues such as skeletal muscle and the liver.
Because the fragment lacks the binding regions for the GH receptor (located in amino acids 1-175), it does not activate the JAK2-STAT5 signaling pathway responsible for hepatic IGF-1 synthesis, somatic growth, or the insulin-antagonistic effects of full-length growth hormone. However, the shorter half-life compared to AOD-9604 (which has an additional stabilizing tyrosine residue) means more frequent dosing is required, and clinical evidence supporting its efficacy in humans remains very limited.
Survodutide
Survodutide activates both GLP-1 and glucagon receptors with a carefully calibrated ratio of agonist activity at each target. The GLP-1 receptor engagement provides the established metabolic benefits of the incretin pathway — centrally mediated appetite suppression, glucose-dependent insulinotropic effects, and delayed gastric emptying — creating a foundation of weight loss and glycemic improvement.
The glucagon receptor component is particularly relevant to survodutide's development focus on MASH (metabolic dysfunction-associated steatohepatitis). Glucagon receptor activation in hepatocytes upregulates mitochondrial beta-oxidation of fatty acids, increases ketone body production, and stimulates amino acid catabolism. This hepatic metabolic shift directly addresses the pathological fat accumulation that defines MASH, reducing intrahepatic triglyceride content by mobilizing stored lipids for energy production rather than continued storage.
Beyond the liver, glucagon signaling increases whole-body energy expenditure through multiple mechanisms: enhanced thermogenesis in brown adipose tissue, increased futile cycling in metabolic pathways, and elevated basal metabolic rate. In clinical trials for MASH, survodutide has demonstrated significant reductions in liver fat content alongside substantial body weight loss. The dual mechanism addresses both the upstream cause (excess caloric intake) and the downstream pathology (hepatic steatosis and inflammation) of metabolic liver disease simultaneously.
Risks & Safety
HGH Fragment 176-191
Common
injection site irritation, headache, brief dizziness.
Serious
extremely limited clinical data, no long-term safety information.
Rare
allergic reactions.
Survodutide
Common
nausea, diarrhea, vomiting, constipation, reduced appetite.
Serious
slightly elevated heart rate, changes in liver enzymes, inflammation of the pancreas, gallstones.
Rare
thyroid concerns (based on similar drugs in animals), severe allergic reactions.
Full Profiles
HGH Fragment 176-191 →
The original, unmodified version of the growth hormone fat-burning fragment — essentially the same concept as AOD-9604 but less stable and shorter-lasting. Contains the part of growth hormone responsible for fat metabolism without the parts that cause growth or blood sugar issues. Requires more frequent dosing than AOD-9604, and has even less clinical evidence supporting its effectiveness.
Survodutide →
A weight loss injection being developed specifically for both obesity and fatty liver disease (MASH). It reduces appetite through one pathway while simultaneously telling your liver to burn its stored fat through another. This dual approach tackles the root cause (eating too much) and the downstream damage (fat build-up in the liver) at the same time. Still in clinical trials.